Kirkland Represents Teva In $5B Ratiopharm Deal

By Erin Marie Daly

Law360, New York (March 18, 2010, 1:28 PM ET) -- In a move designed to help drive its growth in key European markets, Teva Pharmaceutical Industries Ltd. has agreed to fork over $4.93 billion to acquire Ratiopharm GmbH, Germany's second-largest generics maker and the sixth-largest generic-drug company worldwide.

The acquisition, announced Thursday, will boost Teva's European business from sales of $3.3 billion in 2009 to joint pro forma sales of $5.2 billion, the company said.

Following the transaction, Teva will improve its market position in Germany — the world's second-largest generic-drug market, valued at approximately $8.8...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles